Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane Database Syst Rev
Main Authors: Ferrara, Roberto, Imbimbo, Martina, Malouf, Reem, Paget-Bailly, Sophie, Calais, François, Marchal, Corynne, Westeel, Virginie
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2020
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094159/
https://ncbi.nlm.nih.gov/pubmed/33316104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items